EMA Panel Backs Sintilimab for Lung Cancer

Innovent Biologics' Zybrivo, given with chemotherapy, is recommended for advanced non-squamous non-small cell lung cancer in the EU.

Updated on Nov. 16, 2026 in Cancer

Isometric editorial illustration of a single unlabeled amber glass vial beside a clear infusion line on a cream surface, evoking a pharmaceutical approval.
The European Medicines Agency's scientific committee recommended approval of Innovent Biologics' sintilimab, sold as Zybrivo, for advanced lung cancer given with chemotherapy. AI Illustration. Upload story photo >

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization of Zybrivo (sintilimab) in combination with chemotherapy for adults with advanced non-squamous non-small cell lung cancer. The European Commission is expected to issue a final decision in the coming months.

Why it matters

The recommendation follows a Phase 3 trial showing longer survival without disease progression and overall survival for patients receiving the combination, a potential new option for a cancer responsible for about one in five cancer deaths in the EU. If authorized, the treatment would be available across all 27 EU member states, Iceland, Norway and Liechtenstein.

The recommendation rests on a Phase 3 trial of 397 adults, in which sintilimab plus chemotherapy cut the hazard of progression or death by 52% and the hazard of death by 35% compared with placebo plus chemotherapy. No new safety signals were identified, but the European Commission's final decision remains pending.

The players

Innovent Biologics, Inc.

A Chinese biopharmaceutical company that developed sintilimab and is seeking its authorization in the European Union.

European Medicines Agency

The European Union agency responsible for the scientific evaluation and supervision of medicines, whose Committee for Medicinal Products for Human Use issued the recommendation.

The details

Patients in the ORIENT-11 study were randomized 2:1 to receive sintilimab or placebo, each alongside pemetrexed and platinum-based chemotherapy, with progression-free survival as the primary endpoint assessed by a blinded independent radiological review committee. Innovent Biologics announced the positive opinion, its first from the CHMP.

Timeline

  1. November 16, 2026: The CHMP positive opinion was announced by Innovent Biologics.

  2. Coming months: The European Commission is expected to issue a final marketing authorization decision.

Health Landscape

The recommendation advances sintilimab, an anti-PD-1 immunotherapy, through the EMA's centralized authorization pathway that covers new lung cancer treatments across the EU. It adds a chemotherapy-combination option to a treatment landscape increasingly built around immune checkpoint inhibitors.

If authorized, the combination would give adults with advanced non-squamous non-small cell lung cancer in the EU, Iceland, Norway and Liechtenstein a new treatment option alongside chemotherapy. Patients and clinicians will need to await the final Commission decision before the drug can be prescribed.

The takeaway

A positive regulatory opinion is an important step, but patients should consult their oncologists about whether an immunotherapy-chemotherapy combination fits their specific disease profile.

What happens next

The European Commission is expected to issue its final decision on marketing authorization in the coming months.

Further reading

Explore more on Cancer treatments and research developments.

More information

Review the ORIENT-11 trial registry entry (NCT03607539) for study design and enrollment details.